Search

Your search keyword '"Barys, Louise"' showing total 46 results
Start Over Author "Barys, Louise"
46 results on '"Barys, Louise"'

1. Cancer lineage-specific regulation of YAP responsive elements revealed through large-scale functional epigenomic screens

Author

Barbosa, Inês A. M., Gopalakrishnan, Rajaraman, Mercan, Samuele, Mourikis, Thanos P., Martin, Typhaine, Wengert, Simon, Sheng, Caibin, Ji, Fei, Lopes, Rui, Knehr, Judith, Altorfer, Marc, Lindeman, Alicia, Russ, Carsten, Naumann, Ulrike, Golji, Javad, Sprouffske, Kathleen, Barys, Louise, Tordella, Luca, Schübeler, Dirk, Schmelzle, Tobias, and Galli, Giorgio G.

Published
2023
Full Text
View/download PDF

2. Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.

Author

De Bono, Johann S., primary, Morris, Michael J., additional, Sartor, Oliver, additional, Wei, Xiao X., additional, Fizazi, Karim, additional, Herrmann, Ken, additional, Piulats, Josep M., additional, Mahammedi, Hakim, additional, Logothetis, Christopher, additional, George, Daniel J., additional, Eldjerou, Lamis K., additional, Wong, Connie, additional, Barys, Louise, additional, Rajagopal, Nisha, additional, Rodosthenous, Theodoulos, additional, and Chi, Kim N., additional

Published
2024
Full Text
View/download PDF

3. Enhancing the Small-Scale Screenable Biological Space beyond Known Chemogenomics Libraries with Gray Chemical Matter─Compounds with Novel Mechanisms from High-Throughput Screening Profiles

Author

Thomas, Jason R., primary, Shelton, Claude, additional, Murphy, Jason, additional, Brittain, Scott, additional, Bray, Mark-Anthony, additional, Aspesi, Peter, additional, Concannon, John, additional, King, Frederick J., additional, Ihry, Robert J., additional, Ho, Daniel J., additional, Henault, Martin, additional, Hadjikyriacou, Andrea, additional, Neri, Marilisa, additional, Sigoillot, Frederic D., additional, Pham, Helen T., additional, Shum, Matthew, additional, Barys, Louise, additional, Jones, Michael D., additional, Martin, Eric J., additional, Blechschmidt, Anke, additional, Rieffel, Sébastien, additional, Troxler, Thomas J., additional, Mapa, Felipa A., additional, Jenkins, Jeremy L., additional, Jain, Rishi K., additional, Kutchukian, Peter S., additional, Schirle, Markus, additional, and Renner, Steffen, additional

Published
2024
Full Text
View/download PDF

5. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors

Author

Bauer, Todd M, primary, Santoro, Armando, additional, Lin, Chia-Chi, additional, Garrido-Laguna, Ignacio, additional, Joerger, Markus, additional, Greil, Richard, additional, Spreafico, Anna, additional, Yau, Thomas, additional, Goebeler, Maria-Elisabeth, additional, Hütter-Krönke, Marie Luise, additional, Perotti, Antonella, additional, Juif, Pierre-Eric, additional, Lu, Darlene, additional, Barys, Louise, additional, Cremasco, Viviana, additional, Pelletier, Marc, additional, Evans, Helen, additional, Fabre, Claire, additional, and Doi, Toshikiko, additional

Published
2023
Full Text
View/download PDF

6. PAX8 and MECOM are interaction partners driving ovarian cancer

Author

Bleu, Melusine, Mermet-Meillon, Fanny, Apfel, Verena, Barys, Louise, Holzer, Laura, Bachmann Salvy, Marianne, Lopes, Rui, Amorim Monteiro Barbosa, Inês, Delmas, Cecile, Hinniger, Alexandra, Chau, Suzanne, Kaufmann, Markus, Haenni, Simon, Berneiser, Karolin, Wahle, Maria, Moravec, Ivana, Vissières, Alexandra, Poetsch, Tania, Ahrné, Erik, Carte, Nathalie, Voshol, Johannes, Bechter, Elisabeth, Hamon, Jacques, Meyerhofer, Marco, Erdmann, Dirk, Fischer, Matteo, Stachyra, Therese, Freuler, Felix, Gutmann, Sascha, Fernández, César, Schmelzle, Tobias, Naumann, Ulrike, Roma, Guglielmo, Lawrenson, Kate, Nieto-Oberhuber, Cristina, Cobos-Correa, Amanda, Ferretti, Stephane, Schübeler, Dirk, and Galli, Giorgio Giacomo

Published
2021
Full Text
View/download PDF

7. New insights from old data - Hunting for compounds with novel mechanisms using cellular high-throughput screening profiles with Grey Chemical Matter

Author

Thomas, Jason R, primary, Shelton IV, Claude, additional, Murphy, Jason, additional, Brittain, Scott, additional, Bray, Mark-Anthony, additional, Aspesi, Peter, additional, Concannon, John, additional, King, Frederick J, additional, Ihry, Robert J, additional, Ho, Daniel J, additional, Henault, Martin, additional, Hadjikyriacou, Andrea, additional, Neri, Marilisa, additional, Sigoillot, Frederic D, additional, Pham, Helen T, additional, Shum, Matthew, additional, Barys, Louise, additional, Jones, Michael D, additional, Martin, Eric J, additional, Blechschmidt, Anke, additional, Rieffel, Sébastien, additional, Troxler, Thomas J, additional, Mapa, Felipa A, additional, Jenkins, Jeremy L, additional, Jain, Rishi K, additional, Kutchukian, Peter S, additional, Schirle, Markus, additional, and Renner, Steffen, additional

Published
2023
Full Text
View/download PDF

8. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/− mouse model

Author

Chapeau, Emilie A., Gembarska, Agnieszka, Durand, Eric Y., Mandon, Emeline, Estadieu, Claire, Romanet, Vincent, Wiesmann, Marion, Tiedt, Ralph, Lehar, Joseph, deWeck, Antoine, Rad, Roland, Barys, Louise, Jeay, Sebastien, Ferretti, Stephane, Kauffmann, Audrey, Sutter, Esther, Grevot, Armelle, Moulin, Pierre, Murakami, Masato, Sellers, William R., Hofmann, Francesco, and Jensen, Michael Rugaard

Published
2017

9. Data from Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Author

Weiss, Andreas, primary, Lorthiois, Edwige, primary, Barys, Louise, primary, Beyer, Kim S., primary, Bomio-Confaglia, Claudio, primary, Burks, Heather, primary, Chen, Xueying, primary, Cui, Xiaoming, primary, de Kanter, Ruben, primary, Dharmarajan, Lekshmi, primary, Fedele, Carmine, primary, Gerspacher, Marc, primary, Guthy, Daniel Alexander, primary, Head, Victoria, primary, Jaeger, Ashley, primary, Núñez, Eloísa Jiménez, primary, Kearns, Jeffrey D., primary, Leblanc, Catherine, primary, Maira, Sauveur-Michel, primary, Murphy, Jason, primary, Oakman, Helen, primary, Ostermann, Nils, primary, Ottl, Johannes, primary, Rigollier, Pascal, primary, Roman, Danielle, primary, Schnell, Christian, primary, Sedrani, Richard, primary, Shimizu, Toshio, primary, Stringer, Rowan, primary, Vaupel, Andrea, primary, Voshol, Hans, primary, Wessels, Peter, primary, Widmer, Toni, primary, Wilcken, Rainer, primary, Xu, Kun, primary, Zecri, Frederic, primary, Farago, Anna F., primary, Cotesta, Simona, primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Data from Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Author

Weiss, Andreas, primary, Lorthiois, Edwige, primary, Barys, Louise, primary, Beyer, Kim S., primary, Bomio-Confaglia, Claudio, primary, Burks, Heather, primary, Chen, Xueying, primary, Cui, Xiaoming, primary, de Kanter, Ruben, primary, Dharmarajan, Lekshmi, primary, Fedele, Carmine, primary, Gerspacher, Marc, primary, Guthy, Daniel Alexander, primary, Head, Victoria, primary, Jaeger, Ashley, primary, Núñez, Eloísa Jiménez, primary, Kearns, Jeffrey D., primary, Leblanc, Catherine, primary, Maira, Sauveur-Michel, primary, Murphy, Jason, primary, Oakman, Helen, primary, Ostermann, Nils, primary, Ottl, Johannes, primary, Rigollier, Pascal, primary, Roman, Danielle, primary, Schnell, Christian, primary, Sedrani, Richard, primary, Shimizu, Toshio, primary, Stringer, Rowan, primary, Vaupel, Andrea, primary, Voshol, Hans, primary, Wessels, Peter, primary, Widmer, Toni, primary, Wilcken, Rainer, primary, Xu, Kun, primary, Zecri, Frederic, primary, Farago, Anna F., primary, Cotesta, Simona, primary, and Brachmann, Saskia M., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure Legends 1-5 from FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

Author

Guagnano, Vito, primary, Kauffmann, Audrey, primary, Wöhrle, Simon, primary, Stamm, Christelle, primary, Ito, Moriko, primary, Barys, Louise, primary, Pornon, Astrid, primary, Yao, Yao, primary, Li, Fang, primary, Zhang, Yun, primary, Chen, Zhi, primary, Wilson, Christopher J., primary, Bordas, Vincent, primary, Le Douget, Mickaël, primary, Gaither, L. Alex, primary, Borawski, Jason, primary, Monahan, John E., primary, Venkatesan, Kavitha, primary, Brümmendorf, Thomas, primary, Thomas, David M., primary, Garcia-Echeverria, Carlos, primary, Hofmann, Francesco, primary, Sellers, William R., primary, and Graus-Porta, Diana, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table I from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

Author

Weisberg, Ellen, primary, Halilovic, Ensar, primary, Cooke, Vesselina G., primary, Nonami, Atsushi, primary, Ren, Tao, primary, Sanda, Takaomi, primary, Simkin, Irene, primary, Yuan, Jing, primary, Antonakos, Brandon, primary, Barys, Louise, primary, Ito, Moriko, primary, Stone, Richard, primary, Galinsky, Ilene, primary, Cowens, Kristen, primary, Nelson, Erik, primary, Sattler, Martin, primary, Jeay, Sebastien, primary, Wuerthner, Jens U., primary, McDonough, Sean M., primary, Wiesmann, Marion, primary, and Griffin, James D., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table 5 from FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

Author

Guagnano, Vito, primary, Kauffmann, Audrey, primary, Wöhrle, Simon, primary, Stamm, Christelle, primary, Ito, Moriko, primary, Barys, Louise, primary, Pornon, Astrid, primary, Yao, Yao, primary, Li, Fang, primary, Zhang, Yun, primary, Chen, Zhi, primary, Wilson, Christopher J., primary, Bordas, Vincent, primary, Le Douget, Mickaël, primary, Gaither, L. Alex, primary, Borawski, Jason, primary, Monahan, John E., primary, Venkatesan, Kavitha, primary, Brümmendorf, Thomas, primary, Thomas, David M., primary, Garcia-Echeverria, Carlos, primary, Hofmann, Francesco, primary, Sellers, William R., primary, and Graus-Porta, Diana, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figures 1-7 from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

Author

Weisberg, Ellen, primary, Halilovic, Ensar, primary, Cooke, Vesselina G., primary, Nonami, Atsushi, primary, Ren, Tao, primary, Sanda, Takaomi, primary, Simkin, Irene, primary, Yuan, Jing, primary, Antonakos, Brandon, primary, Barys, Louise, primary, Ito, Moriko, primary, Stone, Richard, primary, Galinsky, Ilene, primary, Cowens, Kristen, primary, Nelson, Erik, primary, Sattler, Martin, primary, Jeay, Sebastien, primary, Wuerthner, Jens U., primary, McDonough, Sean M., primary, Wiesmann, Marion, primary, and Griffin, James D., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 1 from Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

Author

Goyal, Lipika, primary, Saha, Supriya K., primary, Liu, Leah Y., primary, Siravegna, Giulia, primary, Leshchiner, Ignaty, primary, Ahronian, Leanne G., primary, Lennerz, Jochen K., primary, Vu, Phuong, primary, Deshpande, Vikram, primary, Kambadakone, Avinash, primary, Mussolin, Benedetta, primary, Reyes, Stephanie, primary, Henderson, Laura, primary, Sun, Jiaoyuan Elisabeth, primary, Van Seventer, Emily E., primary, Gurski, Joseph M., primary, Baltschukat, Sabrina, primary, Schacher-Engstler, Barbara, primary, Barys, Louise, primary, Stamm, Christelle, primary, Furet, Pascal, primary, Ryan, David P., primary, Stone, James R., primary, Iafrate, A. John, primary, Getz, Gad, primary, Porta, Diana Graus, primary, Tiedt, Ralph, primary, Bardelli, Alberto, primary, Juric, Dejan, primary, Corcoran, Ryan B., primary, Bardeesy, Nabeel, primary, and Zhu, Andrew X., primary

Published
2023
Full Text
View/download PDF

16. Data from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

Author

Weisberg, Ellen, primary, Halilovic, Ensar, primary, Cooke, Vesselina G., primary, Nonami, Atsushi, primary, Ren, Tao, primary, Sanda, Takaomi, primary, Simkin, Irene, primary, Yuan, Jing, primary, Antonakos, Brandon, primary, Barys, Louise, primary, Ito, Moriko, primary, Stone, Richard, primary, Galinsky, Ilene, primary, Cowens, Kristen, primary, Nelson, Erik, primary, Sattler, Martin, primary, Jeay, Sebastien, primary, Wuerthner, Jens U., primary, McDonough, Sean M., primary, Wiesmann, Marion, primary, and Griffin, James D., primary

Published
2023
Full Text
View/download PDF

17. Data from Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

Author

Goyal, Lipika, primary, Saha, Supriya K., primary, Liu, Leah Y., primary, Siravegna, Giulia, primary, Leshchiner, Ignaty, primary, Ahronian, Leanne G., primary, Lennerz, Jochen K., primary, Vu, Phuong, primary, Deshpande, Vikram, primary, Kambadakone, Avinash, primary, Mussolin, Benedetta, primary, Reyes, Stephanie, primary, Henderson, Laura, primary, Sun, Jiaoyuan Elisabeth, primary, Van Seventer, Emily E., primary, Gurski, Joseph M., primary, Baltschukat, Sabrina, primary, Schacher-Engstler, Barbara, primary, Barys, Louise, primary, Stamm, Christelle, primary, Furet, Pascal, primary, Ryan, David P., primary, Stone, James R., primary, Iafrate, A. John, primary, Getz, Gad, primary, Porta, Diana Graus, primary, Tiedt, Ralph, primary, Bardelli, Alberto, primary, Juric, Dejan, primary, Corcoran, Ryan B., primary, Bardeesy, Nabeel, primary, and Zhu, Andrew X., primary

Published
2023
Full Text
View/download PDF

18. Data from FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

Author

Guagnano, Vito, primary, Kauffmann, Audrey, primary, Wöhrle, Simon, primary, Stamm, Christelle, primary, Ito, Moriko, primary, Barys, Louise, primary, Pornon, Astrid, primary, Yao, Yao, primary, Li, Fang, primary, Zhang, Yun, primary, Chen, Zhi, primary, Wilson, Christopher J., primary, Bordas, Vincent, primary, Le Douget, Mickaël, primary, Gaither, L. Alex, primary, Borawski, Jason, primary, Monahan, John E., primary, Venkatesan, Kavitha, primary, Brümmendorf, Thomas, primary, Thomas, David M., primary, Garcia-Echeverria, Carlos, primary, Hofmann, Francesco, primary, Sellers, William R., primary, and Graus-Porta, Diana, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figures 1 - 6 from Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

Author

Goyal, Lipika, primary, Saha, Supriya K., primary, Liu, Leah Y., primary, Siravegna, Giulia, primary, Leshchiner, Ignaty, primary, Ahronian, Leanne G., primary, Lennerz, Jochen K., primary, Vu, Phuong, primary, Deshpande, Vikram, primary, Kambadakone, Avinash, primary, Mussolin, Benedetta, primary, Reyes, Stephanie, primary, Henderson, Laura, primary, Sun, Jiaoyuan Elisabeth, primary, Van Seventer, Emily E., primary, Gurski, Joseph M., primary, Baltschukat, Sabrina, primary, Schacher-Engstler, Barbara, primary, Barys, Louise, primary, Stamm, Christelle, primary, Furet, Pascal, primary, Ryan, David P., primary, Stone, James R., primary, Iafrate, A. John, primary, Getz, Gad, primary, Porta, Diana Graus, primary, Tiedt, Ralph, primary, Bardelli, Alberto, primary, Juric, Dejan, primary, Corcoran, Ryan B., primary, Bardeesy, Nabeel, primary, and Zhu, Andrew X., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figures 1-5 from FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

Author

Guagnano, Vito, primary, Kauffmann, Audrey, primary, Wöhrle, Simon, primary, Stamm, Christelle, primary, Ito, Moriko, primary, Barys, Louise, primary, Pornon, Astrid, primary, Yao, Yao, primary, Li, Fang, primary, Zhang, Yun, primary, Chen, Zhi, primary, Wilson, Christopher J., primary, Bordas, Vincent, primary, Le Douget, Mickaël, primary, Gaither, L. Alex, primary, Borawski, Jason, primary, Monahan, John E., primary, Venkatesan, Kavitha, primary, Brümmendorf, Thomas, primary, Thomas, David M., primary, Garcia-Echeverria, Carlos, primary, Hofmann, Francesco, primary, Sellers, William R., primary, and Graus-Porta, Diana, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure Legends from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

Author

Weisberg, Ellen, primary, Halilovic, Ensar, primary, Cooke, Vesselina G., primary, Nonami, Atsushi, primary, Ren, Tao, primary, Sanda, Takaomi, primary, Simkin, Irene, primary, Yuan, Jing, primary, Antonakos, Brandon, primary, Barys, Louise, primary, Ito, Moriko, primary, Stone, Richard, primary, Galinsky, Ilene, primary, Cowens, Kristen, primary, Nelson, Erik, primary, Sattler, Martin, primary, Jeay, Sebastien, primary, Wuerthner, Jens U., primary, McDonough, Sean M., primary, Wiesmann, Marion, primary, and Griffin, James D., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Tables 1-4 from FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

Author

Guagnano, Vito, primary, Kauffmann, Audrey, primary, Wöhrle, Simon, primary, Stamm, Christelle, primary, Ito, Moriko, primary, Barys, Louise, primary, Pornon, Astrid, primary, Yao, Yao, primary, Li, Fang, primary, Zhang, Yun, primary, Chen, Zhi, primary, Wilson, Christopher J., primary, Bordas, Vincent, primary, Le Douget, Mickaël, primary, Gaither, L. Alex, primary, Borawski, Jason, primary, Monahan, John E., primary, Venkatesan, Kavitha, primary, Brümmendorf, Thomas, primary, Thomas, David M., primary, Garcia-Echeverria, Carlos, primary, Hofmann, Francesco, primary, Sellers, William R., primary, and Graus-Porta, Diana, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Tables S1-S3 from Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis

Author

Ito, Moriko, primary, Barys, Louise, primary, O'Reilly, Terence, primary, Young, Sophie, primary, Gorbatcheva, Bella, primary, Monahan, John, primary, Zumstein-Mecker, Sabine, primary, Choong, Peter F., primary, Dickinson, Ian, primary, Crowe, Philip, primary, Hemmings, Christine, primary, Desai, Jayesh, primary, Thomas, David M., primary, and Lisztwan, Joanna, primary

Published
2023
Full Text
View/download PDF

29. Protein destabilization underlies pathogenic missense mutations in ARID1B

Author

Mermet-Meillon, Fanny, Mercan, Samuele, Bauer-Probst, Beatrice, Allard, Cyril, Bleu, Melusine, Calkins, Keith, Knehr, Judith, Altorfer, Marc, Naumann, Ulrike, Sprouffske, Kathleen, Barys, Louise, Sesterhenn, Fabian, and Galli, Giorgio G.

Abstract

ARID1B is a SWI/SNF subunit frequently mutated in human Coffin–Siris syndrome (CSS) and it is necessary for proliferation of ARID1Amutant cancers. While most CSS ARID1Baberrations introduce frameshifts or stop codons, the functional consequence of missense mutations found in ARID1Bis unclear. We here perform saturated mutagenesis screens on ARID1B and demonstrate that protein destabilization is the main mechanism associated with pathogenic missense mutations in patients with Coffin–Siris Syndrome.

Published
2024
Full Text
View/download PDF

30. Pharmacokinetic and pharmacodynamic activity evaluation of MAK683, a selective oral embryonic ectoderm development (EED) inhibitor, in adults with advanced malignancies in a first-in-human study.

Author

Ribrag, Vincent, primary, Wainberg, Zev A., additional, Iglesias Docampo, Lara, additional, Ramkumar, Thiruvamoor, additional, Barys, Louise, additional, Chen, Shuqi, additional, Raccuglia, Marc, additional, Wilbaux, Mélanie, additional, Beltz, Karen, additional, Luyt, Amy, additional, Fan, Yu Yun, additional, Suenaga, Naoko, additional, Luo, Fangjun, additional, Dai, Xuan, additional, Lai, Clinton, additional, and Chen, Jia, additional

Published
2022
Full Text
View/download PDF

31. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Author

Weiss, Andreas, primary, Lorthiois, Edwige, additional, Barys, Louise, additional, Beyer, Kim S., additional, Bomio-Confaglia, Claudio, additional, Burks, Heather, additional, Chen, Xueying, additional, Cui, Xiaoming, additional, de Kanter, Ruben, additional, Dharmarajan, Lekshmi, additional, Fedele, Carmine, additional, Gerspacher, Marc, additional, Guthy, Daniel Alexander, additional, Head, Victoria, additional, Jaeger, Ashley, additional, Núñez, Eloísa Jiménez, additional, Kearns, Jeffrey D., additional, Leblanc, Catherine, additional, Maira, Sauveur-Michel, additional, Murphy, Jason, additional, Oakman, Helen, additional, Ostermann, Nils, additional, Ottl, Johannes, additional, Rigollier, Pascal, additional, Roman, Danielle, additional, Schnell, Christian, additional, Sedrani, Richard, additional, Shimizu, Toshio, additional, Stringer, Rowan, additional, Vaupel, Andrea, additional, Voshol, Hans, additional, Wessels, Peter, additional, Widmer, Toni, additional, Wilcken, Rainer, additional, Xu, Kun, additional, Zecri, Frederic, additional, Farago, Anna F., additional, Cotesta, Simona, additional, and Brachmann, Saskia M., additional

Published
2022
Full Text
View/download PDF

32. Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.

Author

Bauer, Todd Michael, primary, Lin, Chia-Chi, additional, Greil, Richard, additional, Goebeler, Maria-Elisabeth, additional, Huetter-Kroenke, Marie Luise, additional, Garrido-Laguna, Ignacio, additional, Santoro, Armando, additional, Perotti, Antonella, additional, Spreafico, Anna, additional, Yau, Thomas, additional, Joerger, Markus, additional, Cremasco, Viviana, additional, Dostalek, Mirek, additional, Pelletier, Marc, additional, Barys, Louise, additional, Lu, Darlene, additional, Katsanou, Vicky, additional, Fabre, Claire, additional, and Doi, Toshihiko, additional

Published
2021
Full Text
View/download PDF

35. DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway

Author

Dafflon, Caroline, primary, Gaulis, Swann, additional, Barys, Louise, additional, Kapur, Karen, additional, Cornacchione, Vanessa, additional, Schukur, Lina, additional, Bergling, Sebastian, additional, Traggiai, Elisabetta, additional, Jansky, Selina, additional, Hellmann, Leon, additional, Engstler, Barbara Schacher, additional, Kerr, Grainne, additional, Weck, Antoine de, additional, Ruddy, David A., additional, Naumann, Ulrike, additional, Stauffer, Frédéric, additional, Gaul, Christoph, additional, Lin, Ying, additional, Billy, Eric, additional, Weiss, Andreas, additional, Hofmann, Francesco, additional, Ito, Moriko, additional, and Tiedt, Ralph, additional

Published
2020
Full Text
View/download PDF

36. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf −/− mouse model

Author

Chapeau, Emilie A., primary, Gembarska, Agnieszka, additional, Durand, Eric Y., additional, Mandon, Emeline, additional, Estadieu, Claire, additional, Romanet, Vincent, additional, Wiesmann, Marion, additional, Tiedt, Ralph, additional, Lehar, Joseph, additional, de Weck, Antoine, additional, Rad, Roland, additional, Barys, Louise, additional, Jeay, Sebastien, additional, Ferretti, Stephane, additional, Kauffmann, Audrey, additional, Sutter, Esther, additional, Grevot, Armelle, additional, Moulin, Pierre, additional, Murakami, Masato, additional, Sellers, William R., additional, Hofmann, Francesco, additional, and Jensen, Michael Rugaard, additional

Published
2017
Full Text
View/download PDF

37. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

Author

Goyal, Lipika, primary, Saha, Supriya K., additional, Liu, Leah Y., additional, Siravegna, Giulia, additional, Leshchiner, Ignaty, additional, Ahronian, Leanne G., additional, Lennerz, Jochen K., additional, Vu, Phuong, additional, Deshpande, Vikram, additional, Kambadakone, Avinash, additional, Mussolin, Benedetta, additional, Reyes, Stephanie, additional, Henderson, Laura, additional, Sun, Jiaoyuan Elisabeth, additional, Van Seventer, Emily E., additional, Gurski, Joseph M., additional, Baltschukat, Sabrina, additional, Schacher-Engstler, Barbara, additional, Barys, Louise, additional, Stamm, Christelle, additional, Furet, Pascal, additional, Ryan, David P., additional, Stone, James R., additional, Iafrate, A. John, additional, Getz, Gad, additional, Porta, Diana Graus, additional, Tiedt, Ralph, additional, Bardelli, Alberto, additional, Juric, Dejan, additional, Corcoran, Ryan B., additional, Bardeesy, Nabeel, additional, and Zhu, Andrew X., additional

Published
2017
Full Text
View/download PDF

38. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

Author

Weisberg, Ellen, primary, Halilovic, Ensar, additional, Cooke, Vesselina G., additional, Nonami, Atsushi, additional, Ren, Tao, additional, Sanda, Takaomi, additional, Simkin, Irene, additional, Yuan, Jing, additional, Antonakos, Brandon, additional, Barys, Louise, additional, Ito, Moriko, additional, Stone, Richard, additional, Galinsky, Ilene, additional, Cowens, Kristen, additional, Nelson, Erik, additional, Sattler, Martin, additional, Jeay, Sebastien, additional, Wuerthner, Jens U., additional, McDonough, Sean M., additional, Wiesmann, Marion, additional, and Griffin, James D., additional

Published
2015
Full Text
View/download PDF

39. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

Author

Chapeau, Emilie A., Gembarska, Agnieszka, Durand, Eric Y., Mandon, Emeline, Estadieu, Claire, Romanet, Vincent, Wiesmann, Marion, Tiedt, Ralph, Lehar, Joseph, de Weck, Antoine, Rad, Roland, Barys, Louise, Jeay, Sebastien, Ferretti, Stephane, Kauffmann, Audrey, Sutter, Esther, Grevot, Armelle, Moulin, Pierre, Murakami, Masato, and Sellers, William R.

Subjects
MUTAGENESIS, LABORATORY mice, TRANSPOSONS, COHORT analysis, PHARMACOLOGY
Abstract

Inhibitors of double minute 2 protein (MDM2)-tumor protein 53 (TP53) interaction are predicted to be effective in tumors in which the TP53 gene is wild type, by preventing TP53 protein degradation. One such setting is represented by the frequent CDKN2A deletion in human cancer that, through inactivation of p14ARF, activates MDM2 protein, which in turn degrades TP53 tumor suppressor. Here we used piggyBac (PB) transposon insertional mutagenesis to anticipate resistance mechanisms occurring during treatment with the MDM2-TP53 inhibitor HDM201. Constitutive PB mutagenesis in Arf-/- mice provided a collection of spontaneous tumors with characterized insertional genetic landscapes. Tumors were allografted in large cohorts of mice to assess the pharmacologic effects of HDM201. Sixteen out of 21 allograft models were sensitive to HDM201 but ultimately relapsed under treatment. A comparison of tumors with acquired resistance to HDM201 and untreated tumors identified 87 genes that were differentially and significantly targeted by the PB transposon. Resistant tumors displayed a complex clonality pattern suggesting the emergence of several resistant subclones. Among the most frequent alterations conferring resistance, we observed somatic and insertional loss-of-function mutations in transformation-related protein 53 (Trp53) in 54% of tumors and transposonmediated gain-of-function alterations in B-cell lymphoma-extra large (Bcl-xL), Mdm4, and two TP53 family members, resulting in expression of the TP53 dominant negative truncations △NTrp63 and △NTrp73. Enhanced BCL-xL and MDM4 protein expression was confirmed in resistant tumors, as well as in HDM201-resistant patient-derived tumor xenografts. Interestingly, concomitant inhibition of MDM2 and BCL-xL demonstrated significant synergy in p53 wild-type cell lines in vitro. Collectively, our findings identify several potential mechanisms by which TP53 wild-type tumors may escape MDM2-targeted therapy. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

40. Abstract 2909: A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models

Author

Jeay, Sebastien, primary, Gaulis, Swann, additional, Ferretti, Stéphane, additional, Albrecht, Geneviève, additional, Barys, Louise, additional, Guthy, Daniel, additional, Halilovic, Ensar, additional, Ito, Moriko, additional, Murakami, Masato, additional, Pornon, Astrid, additional, Ruetz, Stephan, additional, Venkatesan, Kavitha, additional, Yu, Jianjun, additional, Jensen, Michael, additional, Wiesmann, Marion, additional, Wuerthner, Jens, additional, and Graus-Porta, Diana, additional

Published
2014
Full Text
View/download PDF

41. Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis

Author

Ito, Moriko, Barys, Louise, O'Reilly, Terence, Young, Sophie, Gorbatcheva, Bella, Monahan, John, Zumstein-Mecker, Sabine, Choong, Peter F., Dickinson, Ian, Crowe, Philip, Hemmings, Christine, Desai, Jayesh, Ito, Moriko, Barys, Louise, O'Reilly, Terence, Young, Sophie, Gorbatcheva, Bella, Monahan, John, Zumstein-Mecker, Sabine, Choong, Peter F., Dickinson, Ian, Crowe, Philip, Hemmings, Christine, and Desai, Jayesh

Published
2011

42. The Tyrosine Phosphatase PTPN14 Is a Negative Regulator of YAP Activity

Author

Michaloglou, Chrysiis, primary, Lehmann, Waltraut, additional, Martin, Typhaine, additional, Delaunay, Clara, additional, Hueber, Andreas, additional, Barys, Louise, additional, Niu, Honglin, additional, Billy, Eric, additional, Wartmann, Markus, additional, Ito, Moriko, additional, Wilson, Christopher J., additional, Digan, Mary Ellen, additional, Bauer, Andreas, additional, Voshol, Hans, additional, Christofori, Gerhard, additional, Sellers, William R., additional, Hofmann, Francesco, additional, and Schmelzle, Tobias, additional

Published
2013
Full Text
View/download PDF

43. FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

Author

Guagnano, Vito, primary, Kauffmann, Audrey, additional, Wöhrle, Simon, additional, Stamm, Christelle, additional, Ito, Moriko, additional, Barys, Louise, additional, Pornon, Astrid, additional, Yao, Yao, additional, Li, Fang, additional, Zhang, Yun, additional, Chen, Zhi, additional, Wilson, Christopher J., additional, Bordas, Vincent, additional, Le Douget, Mickaël, additional, Gaither, L. Alex, additional, Borawski, Jason, additional, Monahan, John E., additional, Venkatesan, Kavitha, additional, Brümmendorf, Thomas, additional, Thomas, David M., additional, Garcia-Echeverria, Carlos, additional, Hofmann, Francesco, additional, Sellers, William R., additional, and Graus-Porta, Diana, additional

Published
2012
Full Text
View/download PDF

44. Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis

Author

Ito, Moriko, primary, Barys, Louise, additional, O'Reilly, Terence, additional, Young, Sophie, additional, Gorbatcheva, Bella, additional, Monahan, John, additional, Zumstein-Mecker, Sabine, additional, Choong, Peter F., additional, Dickinson, Ian, additional, Crowe, Philip, additional, Hemmings, Christine, additional, Desai, Jayesh, additional, Thomas, David M., additional, and Lisztwan, Joanna, additional

Published
2011
Full Text
View/download PDF

46. Automation for higher throughput in protein expression: visions, facts and fictions.

Author

Mahnke, Marion, Schlaeppi, Jean Marc, Pouliquen, Yann, Barys, Louise, Rolvering, Catherine, Henke, Mario, Schmitz, Rita, Geisse, Sabine, and Kolbinger, Frank

Subjects
AUTOMATION
Abstract

An abstract of the article "Automation for Higher Throughput in Protein Expression: Visions, Facts and Fictions," by Marion Mahnke, Jean Marc Schlaeppi, Yann Pouliquen, Louise Barys, Catherine Rolvering, Mario Henke, Rita Schmitz, Sabine Geisse, and Frank Kolbinger is presented.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results